Showing results (11-20 of 72) with videos related to
Sort By:
Pageof 8
Revue Medicale Suisse|August 24, 2018
[SGLT2 inhibitor or GLP-1 receptor agonist in a type 2 diabetic patient with cardiovascular disease ?]André J Scheen, Nicolas PaquotRevue Medicale Suisse|August 25, 2017
[DPP-4 or SGLT2 inhibitor added to metformin alone in type 2 diabetes]Nicolas Paquot, André J ScheenRevue Medicale Suisse|September 22, 2010
[Multirisk approach of the type 2 diabetic patient: controversies surrounding target values after the ACCORD trial]André J Scheen, Nicolas PaquotRevue Medicale Suisse|September 2, 2024
[Innovative therapeutic drug combination for type 2 diabetes at cardiorenal risk]André J Scheen, Nicolas PaquotRevue Medicale Suisse|August 25, 2021
[Potentiation of weight reduction with GLP-1 receptor agonists]André J Scheen, Nicolas PaquotCurrent Opinion in Clinical Nutrition and Metabolic Care|June 11, 2008
Inhibitors of cannabinoid receptors and glucose metabolismAndré J Scheen, Nicolas PaquotRevue Medicale Suisse|October 3, 2014
[Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes]André J Scheen, Nicolas PaquotRevue Medicale Suisse|August 28, 2020
[Management of patients with type 2 diabetes at cardiovascular and renal risk : ESC versus ADA-EASD]André J Scheen, Nicolas PaquotRevue Medicale Suisse|July 4, 2017
[Gliptin-gliflozin combination for treating type 2 diabetes]André J Scheen, Nicolas PaquotRevue Medicale Suisse|August 25, 2017
[Therapeutic options for a type 2 diabetic patient not well controlled with metformin plus basal insulin]André J Scheen, Nicolas PaquotPageof 8